

# Stroke

American Stroke  
Association<sup>SM</sup>

JOURNAL OF THE AMERICAN HEART ASSOCIATION

A Division of American  
Heart Association



## **Pharmacological Induction of Ischemic Tolerance by Glutamate Transporter-1 (EAAT2) Upregulation**

Kon Chu, Soon-Tae Lee, Dong-In Sinn, Song-Yi Ko, Eun-Hee Kim, Jeong-Min Kim, Se-Jeong Kim, Dong-Kyu Park, Keun-Hwa Jung, Eun-Cheol Song, Sang Kun Lee, Manho Kim and Jae-Kyu Roh

*Stroke* 2007;38;177-182; originally published online Nov 22, 2006;

DOI: 10.1161/01.STR.0000252091.36912.65

Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75214  
Copyright © 2007 American Heart Association. All rights reserved. Print ISSN: 0039-2499. Online  
ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://stroke.ahajournals.org/cgi/content/full/38/1/177>

Subscriptions: Information about subscribing to Stroke is online at  
<http://stroke.ahajournals.org/subscriptions/>

Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050. Fax: 410-528-8550. E-mail:  
[journalpermissions@lww.com](mailto:journalpermissions@lww.com)

Reprints: Information about reprints can be found online at  
<http://www.lww.com/reprints>

# Pharmacological Induction of Ischemic Tolerance by Glutamate Transporter-1 (EAAT2) Upregulation

Kon Chu, MD; Soon-Tae Lee, MD; Dong-In Sinn, MD; Song-Yi Ko, MS; Eun-Hee Kim, MS; Jeong-Min Kim, MD; Se-Jeong Kim, MS; Dong-Kyu Park, BS; Keun-Hwa Jung, MD; Eun-Cheol Song, MD; Sang Kun Lee, MD, PhD; Manho Kim, MD, PhD; Jae-Kyu Roh, MD, PhD

**Background and Purpose**—Astrocytic glutamate transporter protein, GLT-1 (EAAT2), recovers extracellular glutamate and ensures that neurons are protected from excess stimulation. Recently,  $\beta$ -lactam antibiotics, like ceftriaxone (CTX), were reported to induce the upregulation of GLT-1. Here, we investigated ischemic tolerance induction by CTX in an experimental model of focal cerebral ischemia.

**Methods**—CTX (200 mg/kg per day, IP) was administered for 5 consecutive days before transient focal ischemia, which was induced by intraluminal thread occlusion of the middle cerebral artery for 90 minutes or permanently.

**Results**—Repeated CTX injections enhanced GLT-1 mRNA and protein expressions after 3 and 5 days of treatment, respectively. CTX-pretreated animals showed a reduction in infarct volume by 58% (reperfusion) and 39% (permanent), compared with the vehicle-pretreated animals at 24 hours postischemia ( $P < 0.01$ ). Lower doses of CTX (20 mg/kg per day and 100 mg/kg per day) reduced infarct volumes to a lesser degree. The injection of GLT-1 inhibitor (dihydrokainate) at 30 minutes before ischemia ameliorated the effect of CTX pretreatment. However, CTX administration at 30 minutes after ischemia produced no significant reduction in infarct volume. CTX reduced the levels of proinflammatory cytokines (tumor necrosis factor- $\alpha$ , FasL), matrix metalloproteinase (MMP)-9, and activated caspase-9 ( $P < 0.01$ ). In addition, CTX-pretreated animals showed better functional recovery at day 1 to week 5 after ischemia ( $P < 0.05$ ).

**Conclusions**—This study presents evidence that CTX induces ischemic tolerance in focal cerebral ischemia and that this is mediated by GLT-1 upregulation. (*Stroke*. 2007;38:177-182.)

**Key Words:** ceftriaxone ■ cerebral ischemia ■ excitotoxicity ■ ischemic tolerance ■ glutamate transporter-1

Cell death after cerebral ischemic insult can be induced in 3 ways: (1) by excitation (excitotoxicity), (2) by oxidative stress with free radicals, and (3) by apoptosis.<sup>1</sup> When the brain fails to generate sufficient ATP and this results in energy failure, ionic gradients are lost.<sup>1</sup> At this stage, glutamate is released, reuptake processes are impaired, and glutamate binds to its postsynaptic receptors and promotes excitotoxic processes as well as a radical-induced apoptotic course.<sup>1</sup> Thus, a number of NMDA receptor antagonists have been developed and used for the treatment of neurological diseases in patients, but all have failed clinical trials because of intolerable side effects or a lack of medical efficacy.<sup>2</sup>

Glutamate transporters play a crucial role in removing glutamate released from synaptic clefts.<sup>3</sup> Released glutamate is taken up by glial cells and metabolized to glutamine, which is then transported back into neurons, converted to glutamate,

and sequestered into synaptic vesicles by vesicular glutamate transporters.<sup>4</sup> In addition, it has been demonstrated that glutamate transporter-1 (GLT-1; EAAT2) and glutamate/aspartate transporter, both glial isoforms, are the predominant means of functional glutamate transport, and that they are essential for maintaining low extracellular glutamate, preventing chronic glutamate neurotoxicity,<sup>3,4,5</sup> and for neuronal survival in the ischemic penumbra.<sup>5,6</sup> Recently and unexpectedly, it was postulated that  $\beta$ -lactam antibiotics are potent stimulators of GLT-1 expression.<sup>7</sup> Moreover, ceftriaxone (CTX), which efficiently penetrates the blood-brain barrier, was found to be neuroprotective in vitro when administered under oxygen-glucose deprived conditions, and in an in vivo mouse model of amyotrophic lateral sclerosis.<sup>7</sup> Thus, based on the findings of this study, we investigated whether GLT-1 upregulation induced by CTX can induce ischemic tolerance

Received June 13, 2006; final revision received August 23, 2006; accepted September 15, 2006.

From the Stroke & Neural Stem Cell Laboratory in the Clinical Research Institute (K.C., S.T.L., D.-I.S., S.-Y.K., E.-H.K., J.-M.K., S.-J.K., D.-K.P., K.-H.J., E.-C.S., S.K.L., M.K., J.-K.R.), Stem Cell Research Center, Department of Neurology, Seoul National University Hospital, Seoul, South Korea; the Program in Neuroscience (K.C., S.-T.L., K.-H.J., E.-C.S., S.K.L., M.K., J.-K.R.), Neuroscience Research Institute of the SNUMRC, Seoul National University, Seoul, South Korea; and the Center for Alcohol and Drug Addiction Research (S.-T.L.), Seoul National Hospital, Seoul, South Korea.

The first two authors contributed equally to this work.

Correspondence to Jae-Kyu Roh, MD, PhD, Department of Neurology, Seoul National University Hospital, 28, Yongon-Dong, Chongro-Gu, Seoul, 110-744, South Korea. E-mail rohjk@snu.ac.kr

© 2006 American Heart Association, Inc.

Stroke is available at <http://www.strokeaha.org>

DOI: 10.1161/01.STR.0000252091.36912.65

and improve functional recovery in experimental focal cerebral ischemia.

## Materials and Methods

### Animal Model and Experimental Protocol

All procedures were carried out according to an institutionally approved protocol, and in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Sprague-Dawley male rats (n=103) weighing 220 to 230 g (Daehan Bio; Seoul, Korea) were used, and randomly assigned to the following experimental groups: CTX+normal control (n=18; <sup>CTX</sup>normal group); CTX+reperfusion ischemia (n=23; <sup>CTX</sup>reperfusion group); CTX+permanent ischemia (n=9; <sup>CTX</sup>permanent group); vehicle+reperfusion ischemia (n=23; <sup>vehicle</sup>reperfusion group); vehicle+permanent ischemia (n=9; <sup>vehicle</sup>permanent group); reperfusion ischemia+post-treatment of CTX (n=9; <sup>CTX-post</sup>reperfusion group). Lower dose injection (20 mg/kg per day, 100 mg/kg per day, n=9 respectively); and GLT-1 inhibitor study (<sup>CTX</sup>DHK group, <sup>vehicle</sup>DHK group, n=9 per group).

To determine the optimal time required for CTX to induce maximal GLT upregulation, in a pilot study we injected CTX (200 mg/kg, IP) for up to 7 days preoperatively (n=18). CTX dose and treatment schedules were chosen based on the findings of a previous study.<sup>7</sup> For GLT-1 RT-PCR and western blotting experiments, rats were euthanized at 6 hours, and at 1, 2, 3, 5, and 7 days after the first CTX injection.

Based on this pilot study, we injected CTX (200 mg/kg per day, in PBS; CJ Pharmaceuticals) or PBS (vehicle) into rats intraperitoneally for 5 days before ischemia (total 5 days). The rats for behavioral tests were also injected for additional 3 days postischemia (total 8 days). For comparison purposes, we included the <sup>CTX-post</sup>reperfusion group, in which daily CTX was started at 30 minutes after the ischemic insult. The lower doses of CTX (20 mg/kg per day, 100 mg/kg per day, n=9 respectively) were also tested to evaluate dosage-effects. All other injections of CTX were at 200 mg/kg per day. To verify the causal role of GLT-1 upregulation in neuroprotection, some rats were injected once with the selective GLT-1 inhibitor, dihydrokainate (DHK, 10 mg/kg, IP; Tocris), at 30 minutes before the ischemia induction (<sup>CTX</sup>DHK group, <sup>vehicle</sup>DHK group). The glial transporter GLT1 is inhibited potentially by DHK.<sup>8</sup>

Transient focal cerebral ischemia was induced by the intraluminal occlusion of the middle cerebral artery (MCAo) using a thread for 90 minutes in both groups, as described elsewhere.<sup>9</sup> For comparison, permanent focal cerebral ischemia was induced by leaving the intraluminal filament in position. Physiological parameters, including mean arterial blood pressures, blood gases, and glucose concentrations, were measured throughout surgery. Rectal temperatures were maintained throughout surgery at 37±0.5°C using a thermistor-controlled heated blanket. Animals were maintained in separate cages at room temperature (25°C) with free access to food and water, under a 12-hour light-dark cycle. Modified limb placing tests (MLPT) were performed 1 day before and 1 day after ischemia, and weekly thereafter (n=6 per group) for 5 weeks, as described previously.<sup>10,11</sup> MLPT results were used to assess the sensorimotor integration of forelimbs and hindlimbs by verifying their responses to tactile and proprioceptive stimuli.

### Infarct Volume Measurement

In order to compare infarct sizes in the ischemia-treated groups, we measured infarct volumes (at 24 hours postischemia; n=9 per group) using 2,3,5-triphenyltetrazolium chloride (TTC; Sigma) staining, as described elsewhere.<sup>10</sup> Infarcted and total hemispheric areas of sections were traced from slices taken at 1-mm intervals and measured using an image analysis system (Image-Pro Plus; Media Cybernetics). Two investigators (K.C. and S.T.L.) unaware of study group identities measured infarct sizes using a computerized image analyzer (Bio-Rad). To compensate for the effect of brain edema, corrected infarct volumes were calculated as previously described using: Corrected infarct area=Measured infarct area×{1−[(Ipsilateral hemisphere area−Contralateral hemisphere area)/Contralateral hemi-

sphere]}.<sup>12</sup> Infarct volumes were expressed as percentages of total hemispheric volumes.

### GLT-1 Protein Expression

GLT-1 western blotting was performed as previously described,<sup>13</sup> using anti-GLT-1 antibody (1:200; Santa Cruz) and secondary antibody conjugated with horseradish peroxidase. Anti-β-actin antibody (Santa Cruz) was used as the control. Blots were developed by enhanced chemiluminescence (Pierce), digitally scanned (GS-700; Bio-Rad), and analyzed (Molecular Analyst; Bio-Rad). Relative optical densities were obtained by comparing measured values with the mean values of normal rats.

### RT-PCR for GLT-1 and Inflammatory Mediators

Twenty-four hours after the induction of ischemia, rats were euthanized by decapitation, and brains were immediately extracted (n=4 in each group). RT-PCR for GLT-1, interleukin-6, Fas, FasL, tumor necrosis factor (TNF)-α, and MMP-2/9 were conducted using a previously described method in ischemic hemispheres (for detailed primer sets see supplemental Table I, available online at <http://stroke.ahajournals.org>).<sup>11</sup> mRNA expression levels were normalized versus GAPDH, and relative optical densities were determined by comparing mean measured values with the mean value of the <sup>vehicle</sup>Reperfusion group.

### Measurement of Caspase Activities

Caspase activities were determined using ELISA kits (Caspase-3: Promega; Caspase-8: BD Biosciences; Caspase-9: Chemicon) in ischemic hemispheres, 24 hours after the induction of MCAo (n=4 per group), as previously described.<sup>14</sup> Fluorescent intensities were measured using a plate reader (FL600; Bio-Tek; excitation wavelength: 380 nm; emission wavelength: 460 nm).

### Statistical Analysis

All values are expressed as mean±SD. The analysis was conducted using repeated measures of analysis of variance and the unpaired Student *t* test, if normally distributed (Kolmogorov–Smirnov test; *P*>0.05). Alternatively, we used the Mann–Whitney *U* tests, or specified the test used. A 2-tailed *P* value of <0.05 was considered to be significant.

## Results


### CTX Treatment Upregulated GLT-1 Expression In Vivo

To examine GLT-1 temporal expression profiles in vivo, as a pilot study, we injected CTX daily (200 mg/kg per day, up to 7 days), and euthanized rats at various timepoints (<sup>CTX</sup>normal group, n=18). GLT-1 mRNA expressions in brain increased after CTX administration and peaked after 3 days (1.7-fold), whereas GLT-1 protein levels peaked after 5 days of treatment (Figure 1). Based on this result, we decided to administer CTX for 5 days before the ischemic insult.

### CTX Treatment Enhanced Functional Recovery

Physiological parameters, including mean arterial blood pressure, blood gases, serum glucose, and body temperature did not differ significantly between the 2 experimental groups (<sup>vehicle</sup>reperfusion group and <sup>CTX</sup>reperfusion group) before, during, or 30 minutes after MCAo (ANOVA; supplemental Table II, available online at <http://stroke.ahajournals.org>). Overall mortality was 13.5% (<sup>CTX</sup>reperfusion group) versus 15.6% (<sup>vehicle</sup>reperfusion group), and this was limited to the first week postsurgery.

Whereas vehicle-treated rats (<sup>vehicle</sup>reperfusion group) exhibited >6 points according to MLPTs on the first day after



**Figure 1.** A, Western blotting of GLT-1 expression (upper) and RT-PCR (lower) of GLT-1 mRNA, during 7 days of CTX administration. B, The plot depicts the levels of GLT-1 protein and mRNA serially. GLT-1 protein levels peaked after 5 days of CTX administration.

MCAo, CTX-treated rats (CTX reperfusion group) exhibited less profound deficits ( $P < 0.05$ ; Student *t* test; Figure 2a). Moreover, the CTX reperfusion group continued to recover, and MLPT differences between the 2 groups remained significant until at least 5 weeks after MCAo induction ( $P < 0.01$ ; *t* test). At week 5, the CTX reperfusion group had the MLPT score of  $< 1$ .

**CTX Pretreatment Reduced Infarct Volume**

The CTX reperfusion group exhibited a reduced infarct volume (by 58%) versus the vehicle reperfusion group, at 24 hours postischemia (Figure 2b). The corrected mean infarct volume in CTX reperfusion group (CTX: 200 mg/kg per day) was  $98.1 \pm 32.4 \text{ mm}^3$  versus  $235.5 \pm 80.6 \text{ mm}^3$  in the vehicle reperfusion group ( $P < 0.01$ ). When we injected lower doses of CTX, the infarct volume of rats injected with 20 mg/kg per day of CTX was  $167.1 \pm 45.5 \text{ mm}^3$  ( $P < 0.05$  versus vehicle reperfusion group), and that of 100 mg/kg per day of CTX was  $122.1 \pm 38.8 \text{ mm}^3$  ( $P < 0.01$  versus vehicle reperfusion group). The difference between 100 mg/kg per day and 200 mg/kg per day was not significant ( $P = 0.226$ ).


When we injected dihydrokainate (a selective GLT-1 inhibitor) at 30 minutes before ischemia induction into rats pretreated with CTX (200 mg/kg) for 5 days (CTXDHK group), the mean infarct volume ( $220.6 \pm 43.6 \text{ mm}^3$ ) was found to be larger than in the CTX reperfusion ( $P < 0.01$ ) and similar to that in the vehicle reperfusion ( $P = 0.775$ ; Figure 2b). Dihydrokainate injection without CTX-pretreatment (vehicleDHK group) showed no significant difference in mean infarct volume

( $207.9 \pm 30.5 \text{ mm}^3$ ) versus the vehicle reperfusion group. These results suggest the causal role of GLT-1 upregulation in the ischemic tolerance induced by CTX.

Mean infarct volume in the CTX-post reperfusion group was not different from that of the vehicle reperfusion group ( $P = 0.87$ ), thus showing that post-treatment with CTX had no effect on infarct size (Figure 2c). The CTX permanent group exhibited reduced infarct volumes (by 39%) versus the vehicle permanent group, at 24 hours after ischemic insult (Figure 2d). The corrected mean infarct volume in the CTX permanent group was  $165.2 \pm 35.1 \text{ mm}^3$  versus  $269.5 \pm 55.3 \text{ mm}^3$  in the vehicle permanent group ( $P < 0.01$ ).

**CTX Treatment Reduced Caspase-9 Activity and Downregulated Proinflammatory Cytokines**

Caspase-9 activity in the ischemic hemisphere was significantly reduced in the CTX reperfusion group versus the vehicle reperfusion group (62% decrease;  $P < 0.01$ ; Figure 3a). However, the activities of caspases-8 and 3 were not changed by ceftriaxone treatment. We measured the mRNA expressions of cytokine-related genes, namely, TNF- $\alpha$ , Fas, FasL and interleukin-6, and relative optical density analysis revealed that the CTX reperfusion group showed an 86% decrease in the levels of TNF- $\alpha$ , and a 78% reduction in FasL mRNA levels versus the vehicle reperfusion group ( $P < 0.01$ ; Figure 3b and 3c). The levels of Fas and interleukin-6 mRNA were unchanged by CTX pretreatment. In addition, we analyzed the mRNA levels of the proteolytic enzymes (MMP-2 and MMP-9), and found that MMP-2 levels were unchanged, but that MMP-9



**Figure 2.** <sup>CTX</sup>reperfusion group showed the reduced initial neurological deficit and the enhanced functional recovery over a 5-week period (A). <sup>CTX</sup>reperfusion group also exhibited a reduced infarct volume as compared with <sup>vehicle</sup>reperfusion group (B). Lower doses of CTX (20 mg/kg per day, 100 mg/kg per day) reduced infarction volumes to a lesser degree. The selective GLT-1 inhibitor, dihydrokainate, attenuated the ischemic tolerance induced by CTX, suggesting the causal role of GLT-1 upregulation (B). <sup>CTX-post</sup>reperfusion group showed no neuroprotective effect (C). In <sup>CTX</sup>reperfusion group, infarct volume reductions were also significant but less prominent than in the reperfusion model (D). \*\**P*<0.01 versus <sup>vehicle</sup>reperfusion group in (A). \**P*<0.05 and \*\**P*<0.01 in (B) and (D). ns indicates statistically not significant.


mRNA levels were reduced by 95% attributable to CTX pretreatment.

### Discussion

In this study, we investigated the neuroprotective effect of GLT-1 upregulation during cerebral ischemia. CTX treatment was found to upregulate GLT-1 and to reduce infarct volumes in both transient and permanent cerebral ischemic models. Moreover, the inhibition of GLT-1 ameliorated the ischemic tolerance induced by CTX, and post-treatment with CTX at 30 minutes after ischemia failed to reduce infarct volume. These results suggest that the mechanism of neuroprotection

is based on GLT-1 upregulation. In addition, reduced infarct volumes corresponded with improved and sustained neurological outcomes.

Extracellular glutamate concentrations showed transient elevations immediately (within 30 minutes) after an ischemic insult.<sup>15</sup> In a reperfusion model, this initial peak in glutamate levels was followed by 2 secondary elevations in glutamate at 50 minutes and 90 minutes after initiating reperfusion.<sup>15</sup> However, although glutamate-induced excitotoxicity is a crucial component of the initial ischemic insult, all tested antiglutamatergic drugs have failed in clinical trials.<sup>2</sup> One of the reasons for this failure might be the rapid and early



**Figure 3.** Caspase activities and the expression profiles of inflammatory mediators. <sup>CTX</sup>reperfusion group showed a reduction of caspase-9 activity (A). However, caspase-3 and -8 activities were unchanged. FasL, TNF- $\alpha$ , and MMP-9 mRNA levels were also reduced in <sup>CTX</sup>reperfusion group versus those in the <sup>vehicle</sup>reperfusion group (B and C). \* $P < 0.05$ , \*\* $P < 0.01$  versus the <sup>vehicle</sup>reperfusion group.

increase in extracellular glutamate after ischemia, whereas drugs are administered several hours after the event. In the present study, CTX had already increased GLT-1 expression at the time of ischemia, and as such GLT-1 was available to attenuate excitotoxicity. In addition, glutamate release occurs

more than once during the early reperfusion phase.<sup>15</sup> Thus, increased GLT-1 levels by CTX explain the enhanced neuroprotection (reduced infarct volume) observed in the <sup>CTX</sup>reperfusion group versus the <sup>CTX</sup>permanent group.

There are at least 5 subtypes of glutamate transporters in the mammalian central nervous system.<sup>16</sup> GLT-1 is the predominant subtype and is responsible for the bulk of glutamate reuptake.<sup>16</sup> Moreover, the infusion of GLT-1 antisense led to a significant increase in infarct volumes after reperfusion in a rat ischemia model and a severe neurological deterioration.<sup>17</sup> On the other hand, the neuronal glutamate transporter, EAAC-1 antisense, did not influence ischemic injury.<sup>17</sup> Ischemic preconditioning depends on the expression of astrocytic GLT-1 and the level of its reverse operation.<sup>18</sup> Because glutamate transporters are dynamic proteins that can release or uptake glutamate, their function depends on their regional and cellular localizations, cerebral energy statuses, and the durations and types of neuronal insults. It is known that the reversal of GLT-1 contributes to ischemia-induced increases in excitatory amino acids in the ischemic core.<sup>19</sup> GLT-1 upregulation by CTX might worsen extracellular excitatory amino acids levels in situations of transporter reversal. However, excitatory amino acids release through reversed GLT-1 may not be significant in the ischemic penumbra because dihydrokainate did not reduce excitatory amino acids release in mild ischemic areas, suggesting a diminished transporter reversal role in the penumbra.<sup>19</sup> The normal function of GLT-1, rather than the reversed operation of GLT-1 transporter, seems to dominate in the ischemic penumbra. Our study also suggests that the enhanced expression of GLT-1 exerts a beneficial effect on the ischemic brain.

The relation between GLT-1 and inflammation is not fully understood. Reactive astrocytes express inflammatory makers, such as the inducible forms of nitric oxide synthase and cyclooxygenase, and secrete proapoptotic mediators, such as FasL, and downregulate GLT-1.<sup>20–22</sup> Meanwhile, TNF- $\alpha$  plays a facilitatory role in glutamate excitotoxicity, both directly and indirectly, by inhibiting glial glutamate transporters on astrocytes. TNF- $\alpha$  also has direct effects on glutamate transmission, such as by increasing the expression of AMPA receptors on synapses.<sup>23</sup> In addition, we previously presented evidence that NMDA blocker can reduce endogenous tissue plasminogen activator (tPA) and MMP-9 expressions.<sup>11</sup> In the present study, we found that GLT-1 upregulation reduced the expressions of TNF- $\alpha$ , FasL, and MMP-9. Accordingly, we suggest that the clearance of extracellular glutamate by upregulated GLT-1 might synergistically reduce inflammation and apoptosis. However, caspase-3 levels were not reduced by CTX in the present study, and CTX might influence other cell death pathway such as calpain, which is one of the major cell-death effectors induced by glutamate excitotoxicity in cerebral ischemia.<sup>24</sup> This topic requires further investigations.

The clinical implications of CTX-pretreatment require further discussion. In the amyotrophic lateral sclerosis model, the chronic administration of CTX delayed neuronal loss and muscle strength, and increased mouse survival.<sup>7</sup> However, it needs time to upregulate GLT-1 and therefore is difficult to apply to acute neuroprotection. Thus, instead of using CTX

for acute therapy, it may be applied to induce ischemic tolerance in situations, such as carotid endarterectomy, cardiopulmonary bypass surgery, or in those with a high perioperative risk of ischemic stroke.

For bacterial infections, the usual adult daily dose of CTX is 1 to 2 g given once daily in adults, and 50 to 100 mg/kg once daily in pediatric patients. Thus, the dose used in this study (200 mg/kg per day) is relatively high as compared with clinical practice. Although ceftriaxone has a good tolerability profile, high doses of CTX can cause adverse effects, which include diarrhea, nausea, vomiting, candidiasis, and sometimes reversible biliary pseudolithiasis.<sup>25</sup> However, it has been shown that the EC<sub>50</sub> required to increase GLT1 expression by ceftriaxone is 3.5  $\mu\text{mol/L}$ ,<sup>7</sup> which is comparable to the known central nervous system levels attained during therapy for meningitis (0.3 to 6  $\mu\text{mol/L}$ ).<sup>26</sup> Thus, normal antimicrobial CTX doses are likely to be sufficient to induce GLT-1 upregulation in humans.

In summary, we present evidence that ceftriaxone induces ischemic tolerance in focal cerebral ischemia, which is mediated by GLT-1 upregulation. CTX-induced GLT-1 upregulation might provide a novel antiglutaminergic approach in ischemic stroke.

### Sources of Funding

This study was supported by the Ministry of Health and Welfare (grant No. A060350), Republic of Korea.

### Disclosures

None.

### References

- Lo EH, Moskowitz MA, Jacobs TP. Exciting, radical, suicidal: how brain cells die after stroke. *Stroke*. 2005;36:189–192.
- Wang CX, Shuaib A. NMDA/NR2B selective antagonists in the treatment of ischemic brain injury. *Curr Drug Targets CNS Neurol Disord*. 2005;4:143–151.
- Kanai Y, Hediger MA. The glutamate and neutral amino acid transporter family: physiological and pharmacological implications. *Eur J Pharmacol*. 2003;479:237–247.
- Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RW, Kanai Y, Hediger MA, Wang Y, Schielke JP, Welty DF. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. *Neuron*. 1996;16:675–686.
- Anderson CM, Swanson RA. Astrocyte glutamate transport: review of properties, regulation, and physiological functions. *Glia*. 2000;32:1–14.
- Swanson RA, Liu J, Miller JW, Rothstein JD, Farrell K, Stein BA, Longuemare MC. Neuronal regulation of glutamate transporter subtype expression in astrocytes. *J Neurosci*. 1997;17:932–940.
- Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, Jin L, Dykes Hoberg M, Vidensky S, Chung DS, Toan SV, Bruijn LI, Su ZZ, Gupta P, Fisher PB. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. *Nature*. 2005;433:73–77.
- Pines G, Danbolt NC, Bjoras M, Zhang Y, Bendahan A, Eide L, Koepsell H, Storm-Mathisen J, Seeberg E, Kanner BI. Cloning and expression of a rat brain L-glutamate transporter. *Nature*. 1992;360:464–467.
- Chu K, Kim M, Park KI, Jeong SW, Park HK, Jung KH, Lee ST, Kang L, Lee K, Park DK, Kim SU, Roh JK. Human neural stem cells improve sensorimotor deficits in the adult rat brain with experimental focal ischemia. *Brain Res*. 2004;1016:145–153.
- Lee ST, Chu K, Jung KH, Ko SY, Kim EH, Sinn DI, Lee YS, Lo EH, Kim M, Roh JK. Granulocyte colony-stimulating factor enhances angiogenesis after focal cerebral ischemia. *Brain Res*. 2005;1058:120–128.
- Lee ST, Chu K, Jung KH, Kim J, Kim EH, Kim SJ, Sinn DI, Ko SY, Kim M, Roh JK. Memantine reduces hematoma expansion in experimental intracerebral hemorrhage, resulting in functional improvement. *J Cereb Blood Flow Metab*. 2006;26:536–544.
- Belayev L, Khoutorova L, Deisher TA, Belayev A, Busto R, Zhang Y, Zhao W, Ginsberg MD. Neuroprotective effect of SolCD39, a novel platelet aggregation inhibitor, on transient middle cerebral artery occlusion in rats. *Stroke*. 2003;34:758–763.
- Jung KH, Chu K, Jeong SW, Han SY, Lee ST, Kim JY, Kim M, Roh JK. HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage. *Stroke*. 2004;35:1744–1749.
- Lee SR, Lo EH. Interactions between p38 mitogen-activated protein kinase and caspase-3 in cerebral endothelial cell death after hypoxia-reoxygenation. *Stroke*. 2003;34:2704–2709.
- Yang Y, Li Q, Miyashita H, Yang T, Shuaib A. Different dynamic patterns of extracellular glutamate release in rat hippocampus after permanent or 30-min transient cerebral ischemia and histological correlation. *Neuropathology*. 2001;21:181–187.
- Seal RP, Amara SG. Excitatory amino acid transporters: a family in flux. *Annu Rev Pharmacol Toxicol*. 1999;39:431–456.
- Rao VL, Dogan A, Todd KG, Bowen KK, Kim BT, Rothstein JD, Dempsey RJ. Antisense knockdown of the glial glutamate transporter GLT-1, but not the neuronal glutamate transporter EAAC1, exacerbates transient focal cerebral ischemia-induced neuronal damage in rat brain. *J Neurosci*. 2001;21:1876–1883.
- Kawahara K, Kosugi T, Tanaka M, Nakajima T, Yamada T. Reversed operation of glutamate transporter GLT-1 is crucial to the development of preconditioning-induced ischemic tolerance of neurons in neuron/astrocyte co-cultures. *Glia*. 2005;49:349–359.
- Feustel PJ, Jin Y, Kimelberg HK. Volume-regulated anion channels are the predominant contributors to release of excitatory amino acids in the ischemic cortical penumbra. *Stroke*. 2004;35:1164–1168.
- Grabb MC, Choi DW. Ischemic tolerance in murine cortical cell culture: critical role for NMDA receptors. *J Neurosci*. 1999;19:1657–1662.
- Swanson RA, Ying W, Kauppinen TM. Astrocyte influences on ischemic neuronal death. *Curr Mol Med*. 2004;4:193–205.
- Romera C, Hurtado O, Botella SH, Lizasoain I, Cardenas A, Fernandez-Tome P, Leza JC, Lorenzo P, Moro MA. In vitro ischemic tolerance involves upregulation of glutamate transport partly mediated by the TACE/ADAM17-tumor necrosis factor- $\alpha$  pathway. *J Neurosci*. 2004;24:1350–1357.
- Pickering M, Cumiskey D, O'Connor JJ. Actions of TNF- $\alpha$  on glutamatergic synaptic transmission in the central nervous system. *Exp Physiol*. 2005;90:663–670.
- Kim M, Roh JK, Yoon BW, Kang L, Kim YJ, Aronin N, DiFiglia M. Huntingtin is degraded to small fragments by calpain after ischemic injury. *Exp Neurol*. 2003;183:109–115.
- Lamb HM, Ormrod D, Scott LJ, Figgitt DP. Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections. *Drugs*. 2002;62:1041–1089.
- Nau R, Prange HW, Muth P, Mahr G, Menck S, Kolenda H, Sorgel F. Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninfamed meninges. *Antimicrob Agents Chemother*. 1993;37:1518–1524.